Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Patients with diabetes are at higher risk of cardiovascular diseases and cognitive
impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin …

Alzheimer's disease (AD) is characterized by the accumulation of hyperphosphorylated tau
and amyloid-β (Aβ) protein resulting in synaptic loss and apoptosis. Aβ and tau deposition …

Background The brain was once thought of as an insulin-insensitive organ. We now know
that the insulin receptor is present throughout the brain and serves important functions in …

Gliflozins are a novel class of oral anti-diabetic drugs, acting as inhibitors of sodium-glucose
co-transporters (SGLTs) through the proximal convoluted tubules (PCT) and intestinal …

Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has featured
marked anti-inflammatory effects in murine models of myocardial infarction, renal injury, and …

Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has emerged
as a promising neuroprotective agent in murine models of epilepsy and obesity-induced …

Evidence has demonstrated that a new class of anti-diabetic drugs, sodium-glucose co-
transporter 2 (SGLT2) inhibitors, could exert beneficial effects on atherosclerotic …

It is widely recognized that obesity and associated metabolic changes are considered a risk
factor to age-associated cognitive decline. Inflammation and increased oxidative stress in …

Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in
the USA. The pathogenesis of DKD is multifactorial and involves activation of multiple …